1
|
Gagliardi T, Bishop B, Battisti N, Rusby J, Ring A, Nash T, Allen M, Downey K, Nerurkar A, Tasoulis M. Microcalcifications after neoadjuvant chemotherapy for breast cancer in women achieving pathologic complete response of the invasive disease: do they matter? Breast 2021. [DOI: 10.1016/s0960-9776(21)00184-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
2
|
Irfan T, Turkes F, Asare B, Mohammed K, Osin P, Nerurkar A, Smith I, Parton M, Johnston S, Turner N, Okines A. Clinical Outcomes in Triple-negative Lobular Breast Cancer: a Single-institution Experience. Clin Oncol (R Coll Radiol) 2019. [DOI: 10.1016/j.clon.2019.03.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
3
|
Muscara F, Christaki G, Richardson C, O'Connell R, Padmanabhan P, Warwick J, Lee Y, Smith I, Nerurkar A, Osin P, Krupa K, Rusby J, Roche N, Gui G, MacNeil F, Barry P. Abstract P3-03-14: Clinical utility of one-step nucleic acid amplification (OSNA) in axillary surgery after neoadjuvant chemotherapy (NAC). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-03-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
NAC has been used for downsizing of the tumour in breast and axilla to allow more conservative surgery. In the NAC setting, intraoperative assessment of sentinel lymph node(s) (SLN) is still considered necessary1. Current awareness of the prognostic value for axillary nodal down-staging has renewed interest in analysis of SLN post-NAC.
In this study we want to examine the clinical utility of OSNA (based on CK19 mRNA detection) as a method of intra-operative analysis of SLN to assist real-time decision-making for axillary surgery post-NAC in early breast cancer (EBC).
Methods
Retrospective analysis of prospective data on 399 consecutive patients with EBC who received NAC followed by breast surgery with SLN biopsy (408 axillae) and assessment by OSNA, from September 2011 to January 2018 at the Royal Marsden Hospital (UK). OSNA readouts from the Sysmex RD-100i were collected separate to and blinded from clinico-pathological data. A negative or benign pre-treatment axillary ultrasound scan or indeterminate ultrasound with negative or benign axillary cytology/histology prior to NAC was considered cN0. Univariate analysis (significance at p<0.05) was used to identify risk of recurrence. Patients had a median (mean) follow up of 32.5 (36) months.
Results
The median age at diagnosis was 49 years, median BMI 26, 41 EBC (10%) were screen-detected, 292 (72%) were grade 3 and the most frequent phenotype was receptor triple negative (n=132, 32%).
Of 408 axillae, 248 (60%) were initially cN0, of which 113 (46%) had a pathological complete response (pCR) in the breast. SLN in 54 (22%) cN0 patients were positive on OSNA, of which only 6 (9%) had further involved axillary nodes all 6 of which were ER+ Her2-.
The remaining 160 (40%) axillae were cN1 of which 87 (54%) had conversion to ypN0 including 55 (34%) with both ypT0ypN0.
Axillary lymphadenectomy (AL) was performed in 79 (19%) patients overall, of which n=22 (28%) were cN0 and 57 (72%) were cN1. Of these, 30 (53%) of the cN1 and 6 of 22 (45%) of cN0 had at least 1 additional positive AL node.
Overall 59 (14.4%) patients relapsed. A significantly worse rate of relapse was observed in cN1 compared to cN0 patients (37/159 (23.3%) versus 22/244 (9%), p<0.001). Combined pCR of both breast and axilla (in cN1, n=54) was associated with a significantly reduced risk of relapse and death (p<0.001) compared to those without pCR of either breast or axilla (n=62). Of the latter 18 (29%) relapsed (including 10 deaths).
The mean of both the single highest node tumour load (and total nodal tumour load), as measured by CK19mRNA copies/ul on OSNA, were significantly higher at 90,000 (98,300) for those who relapsed versus 23,100 (25,100) for those without relapse (p=0.027).
Conclusions
The OSNA assay is an accurate tool for axillary SLN analysis in patients after NAC and was helpful in intra-operative axillary management. OSNA reduces the need for a second surgery for AL in 20% of breast cancer patients with a positive-SLN after NAC and might offer additional prognostic value.
Reference
1. NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Breast Cancer.2016.Version 2.2016.
Citation Format: Muscara F, Christaki G, Richardson C, O'Connell R, Padmanabhan P, Warwick J, Lee Y, Smith I, Nerurkar A, Osin P, Krupa K, Rusby J, Roche N, Gui G, MacNeil F, Barry P. Clinical utility of one-step nucleic acid amplification (OSNA) in axillary surgery after neoadjuvant chemotherapy (NAC) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-03-14.
Collapse
Affiliation(s)
- F Muscara
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - G Christaki
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - C Richardson
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - R O'Connell
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - P Padmanabhan
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - J Warwick
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - Y Lee
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - I Smith
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - A Nerurkar
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - P Osin
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - K Krupa
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - J Rusby
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - N Roche
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - G Gui
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - F MacNeil
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| | - P Barry
- Royal Marsden Hospital, London, United Kingdom; University of Warwick, Warwick, United Kingdom
| |
Collapse
|
4
|
Tang SSK, Rapisarda F, Nerurkar A, Osin P, MacNeill F, Smith I, Johnston S, Ross G, Mohammed K, Gui GPH. Complete excision with narrow margins provides equivalent local control to wider excision in breast conservation for invasive cancer. BJS Open 2018; 3:161-168. [PMID: 30957062 PMCID: PMC6433318 DOI: 10.1002/bjs5.50121] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Accepted: 10/22/2018] [Indexed: 11/07/2022] Open
Abstract
Background Society of Surgical Oncology and American Society for Radiation Oncology guidelines define clear margins in breast-conserving therapy (BCT) as 'no ink on tumour', in contrast to the attainment of margins of at least 1 mm widely practised in the UK. The primary aim of this study was to explore clinical, surgical and tumour-related factors associated with local recurrence after BCT, with a secondary aim of assessing the impact of margin re-excision on the risk of local recurrence. Methods Patient demographics, surgical details, tumour characteristics and local recurrence were recorded for consecutive women with BCT undergoing surgery between January 1997 and January 2007. Margins were defined as clear (greater than 1 mm), close (less than 1 mm but no ink on tumour), reaches (ink on tumour) and clear after re-excision. Results A total of 1045 women of median age 54 (range 18-86) years were studied. Median follow-up was 89 (range 4-196) months. Local recurrence occurred in 52 patients (5·0 per cent). Ink on tumour was associated with local recurrence (hazard ratio (HR) 4·86, 95 per cent c.i. 1·49 to 15·79; P = 0·009). Risk of local recurrence was the same for close and clear margins (HR 1·03, 0·40 to 2·62; P = 0·954). In women with involved margins, re-excision was still associated with an increased local recurrence risk (HR 2·50, 1·32 to 4·72; P = 0·005). Oestrogen receptor negativity increased risk (HR 2·28, 1·28 to 4·06; P = 0·005). Conclusion Adequately excised margins, even when under 1 mm, provide equivalent outcomes to wider margins in BCT. Achieving complete excision at primary surgery achieves the lowest rates of local recurrence.
Collapse
Affiliation(s)
- S S K Tang
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - F Rapisarda
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - A Nerurkar
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - P Osin
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - F MacNeill
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - I Smith
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - S Johnston
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - G Ross
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - K Mohammed
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - G P H Gui
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| |
Collapse
|
5
|
Gui G, Agusti A, Twelves D, Tang S, Kabir M, Montgomery C, Nerurkar A, Osin P, Isacke C. INTEND II randomized clinical trial of intraoperative duct endoscopy in pathological nipple discharge. Br J Surg 2018; 105:1583-1590. [PMID: 30238438 DOI: 10.1002/bjs.10990] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2018] [Revised: 05/10/2018] [Accepted: 07/31/2018] [Indexed: 12/13/2022]
Abstract
BACKGROUND The majority of lesions resulting in pathological nipple discharge are benign. Conventional surgery is undirected and targeting the causative lesion by duct endoscopy may enable more accurate surgery with fewer complications. METHODS Patients requiring microdochectomy and/or major duct excision were randomized to duct endoscopy or no duct endoscopy before surgery. Primary endpoints were successful visualization of the pathological lesion in patients randomized to duct endoscopy, and a comparison of the causative pathology between the two groups. The secondary endpoint was to compare the specimen size between groups. RESULTS A total of 68 breasts were studied in 66 patients; there were 31 breasts in the duct endoscopy group and 37 in the no-endoscopy group. Median age was 49 (range 19-81) years. Follow-up was 5·4 (i.q.r. 3·3-8·9) years in the duct endoscopy group and 5·7 (3·1-9·0) years in no-endoscopy group. Duct endoscopy had a sensitivity of 80 (95 per cent c.i. 52 to 96) per cent, specificity of 71 (44 to 90) per cent, positive predictive value of 71 (44 to 90) per cent and negative predictive value of 80 (52 to 96) per cent in identifying any lesion. There was no difference in causative pathology between the groups. Median volume of the surgical resection specimen did not differ between groups. CONCLUSION Diagnostic duct endoscopy is useful for identifying causative lesions of nipple discharge. Duct endoscopy did not influence the pathological yield of benign or malignant diagnoses nor surgical resection volumes. Registered as INTEND II in CancerHelp UK clinical trials database (https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-changes-inside-the-breast-ducts-of-women-who-have-nipple-discharge).
Collapse
Affiliation(s)
- G Gui
- Department of Surgery, Royal Marsden NHS Trust, London, UK
| | - A Agusti
- Department of Surgery, Royal Marsden NHS Trust, London, UK
| | - D Twelves
- Department of Surgery, Royal Marsden NHS Trust, London, UK
| | - S Tang
- Department of Surgery, Royal Marsden NHS Trust, London, UK
| | - M Kabir
- Department of Clinical Research and Development, Royal Marsden NHS Trust, London, UK
| | - C Montgomery
- Department of Surgery, Royal Marsden NHS Trust, London, UK
| | - A Nerurkar
- Department of Histopathology, Royal Marsden NHS Trust, London, UK
| | - P Osin
- Department of Histopathology, Royal Marsden NHS Trust, London, UK
| | - C Isacke
- Institute of Cancer Research, London, UK
| |
Collapse
|
6
|
Kipps E, Irfan T, Fribbens C, Osin P, Nerurkar A, Mohammed K, Parton M, Johnston S, Turner N, Okines A. Metaplastic Breast Cancer (MBC): A Single Centre Experience. Clin Oncol (R Coll Radiol) 2018. [DOI: 10.1016/j.clon.2018.02.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
7
|
Turner NC, Garcia-Murillas I, Chopra N, Beaney M, Kilburn L, Cutts R, Osin P, Nerurkar A, Schiavon G, Hrebien S, Bliss J, Dowsett M, Smith I. Abstract P1-02-01: Circulating tumor DNA analysis to predict relapse and overall survival in early breast cancer – Longer follow-up of a proof-of-principle study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-02-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
In a previous proof-of-principle study we demonstrated that detection of circulating tumour DNA (ctDNA) in the adjuvant setting, after completion of surgery and chemotherapy for early stage breast cancer, was associated with a high risk of early relapse. Here we present longer follow-up of the same series, to define the predictive power of ctDNA analysis for disease free survival, and assess the potential to predict overall survival.
Methods
We recruited a cohort of 55 women presenting with early stage, primary breast cancer, who were all scheduled to receive neo-adjuvant chemotherapy. The primary tumour was sequenced to identify somatic mutations, identifying at least one mutation in 43 patients. Mutations were tracked with digital PCR to identify ctDNA, in plasma samples taken either at a single post-surgical time point (2-6 weeks post-surgery) or with serial plasma samples taken every 6 months in the adjuvant setting.
Results
At a median 31.7 months follow-up, 42% (18/43) patients had relapsed. Detection of ctDNA at the single post-surgical time point was associated with poor disease free survival, HR=13.6 95%CI (4.5, 41.2) p<0.001, and overall survival HR=84.7 95%CI (9.8, 730.4) p<0.001. All patients with ctDNA detected in a single post-surgical time point relapsed and died in the follow-up period (7/7, 100% specificity), although the single post-surgery time point had modest 39% (7/18) sensitivity for relapse. Detection of ctDNA at any point in serial sampling was associated with poor disease free survival HR=25.7 95%CI (8.3, 79.8) p<0.001 and overall survival HR=47.1 95%CI (6.1, 366.1) p<0.001. All patients with ctDNA detected in a serial mutation tracking relapsed in the follow-up period (14/14, 100% specificity), with 78% (14/18) sensitivity for relapse. Sensitivity was limited by 3 cases of brain only relapse and one case of solitary ovarian relapse. Detection of ctDNA in serial sampling had a median lead-time of 8.1 months over clinical relapse.
Conclusion
Detection of ctDNA in the adjuvant setting has a high predictive power for future relapse and death from breast cancer. Therapeutic trials are required to determine whether mutation tracking identifies relapse sufficiently early to allow for further adjuvant therapy.
Citation Format: Turner NC, Garcia-Murillas I, Chopra N, Beaney M, Kilburn L, Cutts R, Osin P, Nerurkar A, Schiavon G, Hrebien S, Bliss J, Dowsett M, Smith I. Circulating tumor DNA analysis to predict relapse and overall survival in early breast cancer – Longer follow-up of a proof-of-principle study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-02-01.
Collapse
Affiliation(s)
- NC Turner
- Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - I Garcia-Murillas
- Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - N Chopra
- Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - M Beaney
- Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - L Kilburn
- Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - R Cutts
- Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - P Osin
- Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - A Nerurkar
- Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - G Schiavon
- Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - S Hrebien
- Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - J Bliss
- Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - M Dowsett
- Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - I Smith
- Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Institute of Cancer Research, London, United Kingdom
| |
Collapse
|
8
|
Sheri A, Smith IE, Johnston SR, A'Hern R, Nerurkar A, Jones RL, Hills M, Detre S, Pinder SE, Symmans WF, Dowsett M. Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. Ann Oncol 2015; 26:75-80. [PMID: 25361988 DOI: 10.1093/annonc/mdu508] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND The purpose of this study was (i) to test the hypothesis that combining Ki67 with residual cancer burden (RCB) following neoadjuvant chemotherapy, as the residual proliferative cancer burden (RPCB), provides significantly more prognostic information than either alone; (ii) to determine whether also integrating information on ER and grade improves prognostic power. PATIENTS AND METHODS A total of 220 patients treated with neoadjuvant chemotherapy for primary breast cancer were included in the study. Analyses employed a Cox proportional hazard model. Prognostic indices (PIs) were created adding in Ki67, grade and ER to RCB. Leave-one-out cross-validation was used to reduce bias. The overall change in χ(2) of the best model for each index was used to compare the prognostic ability of the different indices. RESULTS All PIs provided significant prognostic information for patients with residual disease following neoadjuvant chemotherapy. RPCB (χ(2) = 61.4) was significantly more prognostic than either RCB (χ(2) = 38.1) or Ki67 (χ(2) = 53.8) alone P < 0.001. A PI incorporating RCB, Ki67 grade and ER provided the most prognostic information overall and gave χ(2) = 73.8. CONCLUSIONS This study provides proof of principle that the addition of post-treatment Ki67 to RCB improves the prediction of long-term outcome. Prediction may be further improved by addition of post-treatment grade and ER and warrants further investigation for estimating post-neoadjuvant risk of recurrence. These indices may have utility in stratifying patients for novel therapeutic interventions after neoadjuvant chemotherapy.
Collapse
Affiliation(s)
- A Sheri
- Breast Unit, Royal Marsden Hospital, London; Academic Department of Biochemistry, Royal Marsden Hospital, London; Breakthrough Breast Cancer Research Centre, London.
| | - I E Smith
- Breast Unit, Royal Marsden Hospital, London
| | | | - R A'Hern
- Clinical Trials and Statistics Unit, Institute of Cancer Research, London
| | - A Nerurkar
- Department of Pathology, Royal Marsden Hospital, London, UK
| | - R L Jones
- Division of Medical Oncology, Seattle Cancer Care Alliance, Seattle, USA
| | - M Hills
- Academic Department of Biochemistry, Royal Marsden Hospital, London
| | - S Detre
- Academic Department of Biochemistry, Royal Marsden Hospital, London
| | - S E Pinder
- Department of Research Oncology, Kings College, London, UK
| | - W F Symmans
- Department of Pathology, M.D. Anderson Cancer Centre, USA
| | - M Dowsett
- Breast Unit, Royal Marsden Hospital, London; Academic Department of Biochemistry, Royal Marsden Hospital, London; Breakthrough Breast Cancer Research Centre, London
| |
Collapse
|
9
|
Allen SD, Osin P, Nerurkar A. The radiological excision of high risk and malignant lesions using the INTACT breast lesion excision system. A case series with an imaging follow up of at least 5 years. Eur J Surg Oncol 2014; 40:824-9. [PMID: 24742589 DOI: 10.1016/j.ejso.2014.03.022] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2014] [Revised: 03/14/2014] [Accepted: 03/23/2014] [Indexed: 10/25/2022] Open
Abstract
PURPOSE To evaluate the efficacy of a BLES procedure as a primary excisional biopsy rather than a surgical wide local excision for treatment of a high risk or a malignant lesion. METHODS 41 patients underwent a BLES procedure in order to attempt to remove a small breast lesion using a 15 mm or 20 mm wand from August 2007 to January 2009. The lesions were either proven on prior core biopsy to show high risk or malignant pathology or were considered to be indeterminate or suspicious on ultrasound or mammography. The pathology was reviewed to include the final status of lesion excision. If margin involvement was demonstrated then a formal surgical excision was subsequently recommended. Follow up mammography or ultrasound was performed annually in patients following the final pathological diagnosis. RESULTS 9 patients had a primary diagnosis of atypia (columnar cell change with atypia or atypical ductal hyperplasia (ADH)), 23 patients had ductal carcinoma in situ (DCIS) and 9 had an invasive carcinoma (IC) at the original BLES pathology. Clear BLES margins of >1 mm were obtained in 3/9 atypia lesions, 15/23 DCIS and 0/9 IC. 12/13 low grade DCIS were completely excised. Subsequent surgical margin excisions were undertaken in 20 patients. After at least 5 years of follow up (mean 66 months), 1 lesion had recurred on imaging. CONCLUSION A BLES excision has potential as an alternative technique to traditional surgical wide local excision in the management of certain small breast lesions with high risk and low grade malignant potential.
Collapse
Affiliation(s)
- S D Allen
- Dept of Imaging, Royal Marsden NHS Foundation Trust, United Kingdom.
| | - P Osin
- Dept of Pathology, Royal Marsden NHS Foundation Trust, United Kingdom
| | - A Nerurkar
- Dept of Pathology, Royal Marsden NHS Foundation Trust, United Kingdom
| |
Collapse
|
10
|
Rusby JE, Agabiti E, Waheed S, Barry P, Roche N, Allum W, Gui G, MacNeill F, Christaki G, Osin P, Nerurkar A. Abstract P1-01-11: Is OSNA mRNA copy number in sentinel lymph node biopsy predictive of further disease in the axilla? Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-01-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Intra-operative assessment of sentinel nodes (SLNs) allows immediate completion axillary dissection (cALND) in breast cancer patients. Molecular assessment such as one-step nucleic acid amplication (OSNA) promises greater sensitivity and provides a more accurate quantitative assessment than traditional methods.
Our unit policy is to proceed to cALND in patients with macrometastases but not for micrometastases. However, evidence of upstaging has led us to seek to raise the threshold for proceeding to cALND. The CK19 mRNA copy number is an expression of the metastatic burden in the SLN and may be related to the presence of additional disease in the cALND. Since the original copy number threshold between micro (250–5000 copies/microliter) and macrometastasis (>5000 copies/microliter) was based on few patients and serial pathological sections, we investigated the mRNA copy number in patients with and without additional disease in the cALND.
Methods: All patients in our unit undergo pre-operative axillary ultrasound with fine needle aspiration cytology of any suspicious nodes. Those with malignant cytology proceed directly to ALND. Radiologically and cytologically node negative patients undergo sentinel lymph node biopsy (SLNB) and OSNA. Electronic records of consecutive patients with invasive breast cancer undergoing SLNB with OSNA from August 2011 to March 2012 were retrospectively reviewed. Two parameters of mRNA copy number were examined: Copy number of the highest copy number SLN and the summed copy numbers of all positive SLNs. Their relationship to the presence of further disease in the axilla was examined using Student's t test.
Results: Of 201 SLNBs, 45 (22%) had macrometastasis-positive OSNA and therefore underwent cALND (1 patient declined). Twenty patients (45%) had no further positive nodes (a negative cALND) with a total axillary metastatic burden of 1–2 in 11–27 nodes. Twenty four (55%) showed further disease (a positive cALND) with a burden of 2–20 in 9–30 nodes, including the SLNs.
There was no significant difference in tumour size or grade between patients with additional positive nodes in the cALND compared with those with no further disease.
There was no significant difference in the copy number of the highest copy number positive SLN (p = 0.44) or in the summed copy number of all positive SLNs (p = 0.36) between the cALND positive and negative groups.
Conclusion: OSNA CK19 mRNA copy number does not correlate with the cALND metastatic burden. Therefore, raising the copy number threshold may be too simplistic as a method to better select patients with high probability of a positive cALND. A predictive model will be derived based on multivariate analysis of the larger patient population (>400 patients) that will have undergone SLNB with OSNA by the time of SABCS.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-01-11.
Collapse
Affiliation(s)
- JE Rusby
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - E Agabiti
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - S Waheed
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - P Barry
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - N Roche
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - W Allum
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - G Gui
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - F MacNeill
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - G Christaki
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - P Osin
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - A Nerurkar
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| |
Collapse
|
11
|
Nerurkar A, Bitton A, Davis R, Phillips R, Yeh G. P02.109. Stress management counseling in primary care: results of a national study. BMC Complement Altern Med 2012. [PMCID: PMC3373769 DOI: 10.1186/1472-6882-12-s1-p165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Gui GPH, Twelves D, Nerurkar A, Osin P, Ward A, Isacke CM. Anatomical association of fluid yielding ducts with location of the breast cancer affected segment in screen detected and symptomatic breast cancer. BMC Proc 2009. [PMCID: PMC2727107 DOI: 10.1186/1753-6561-3-s5-s13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
13
|
Gui GPH, Twelves D, Nerurkar A, Osin P, Ward A, Crook T, Isacke CM. A direct comparative study of methylation-specific PCR in ductal lavage fluid, breast cancer tissue, normal breast parenchyma and plasma in women with early breast cancer. BMC Proc 2009. [PMCID: PMC2727119 DOI: 10.1186/1753-6561-3-s5-s20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
14
|
Arnedos M, Nerurkar A, Osin P, A'Hern R, Smith I, Dowsett M. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 2009; 20:1948-52. [DOI: 10.1093/annonc/mdp234] [Citation(s) in RCA: 134] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
|
15
|
Twelves D, Nerurkar A, Osin P, Ward A, Isacke C, Gui G. Anatomical association of fluid yielding ducts with breast cancer location in screen detected and symptomatic breast cancer. Eur J Surg Oncol 2009. [DOI: 10.1016/j.ejso.2009.07.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
16
|
Twelves D, Tang S, Osin P, Nerurkar A, Isacke C, Gui G. Intraductal promoter hypermethylation profiles in breast in cancer. Eur J Surg Oncol 2009. [DOI: 10.1016/j.ejso.2009.07.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
17
|
Hegyi L, Thway K, Newton R, Osin P, Nerurkar A, Hayes AJ, Fisher C. Malignant myoepithelioma arising in adenomyoepithelioma of the breast and coincident multiple gastrointestinal stromal tumours in a patient with neurofibromatosis type 1. J Clin Pathol 2009; 62:653-5. [DOI: 10.1136/jcp.2008.063628] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
18
|
Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, Smith IE. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008; 19:1847-52. [PMID: 18567607 DOI: 10.1093/annonc/mdn395] [Citation(s) in RCA: 173] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND Experimental data suggest that triple-negative (TN) breast cancer may have increased sensitivity to platinum-based chemotherapy but clinical data are limited. We present our long-term results with platinum-based chemotherapy for TN breast cancer. PATIENTS AND METHODS In all, 94 (17 TN), 79 (11 TN) and 155 (34 TN) patients receiving platinum-based chemotherapy in neo-adjuvant/adjuvant and advanced setting were included. Response rates and outcome were compared for TN tumours versus others. RESULTS Neo-adjuvant complete response rates were significantly higher for TN tumours (88%) than others (51%; P = 0.005). The 5-year overall survival (OS) for TN tumours following adjuvant/neo-adjuvant chemotherapy was 64% [95% confidence interval (CI) 44% to 79%] compared with 85% (95% CI 79% to 90%) for others. Five-year disease-free survival for TN tumours was 57% (95% CI 37% to 73%) compared with 72% (95% CI 64% to 78%) for others. For patients with advanced breast cancer, overall response rates were 41% for TN tumours and 31% for others (P = 0.3). Patients with TN tumours had a significantly prolonged progression-free survival of 6 months compared with 4 months for others (P = 0.05), though the OS was not significantly different between the two groups (11 versus 7 months). CONCLUSION Platinum-based chemotherapy achieves increased response rates for TN tumours, with a trend towards worse survival in early breast cancer through an improved survival in advanced disease. Prospective randomised trials are warranted.
Collapse
Affiliation(s)
- B Sirohi
- Breast Unit, Royal Marsden NHS Foundation Trust, London, UK
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, Smith IE. Platinum-based chemotherapy in triple-negative (TN) breast cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Westbury CB, Pearson A, Nerurkar A, Reis-Filho JS, Steele D, Peckitt C, Sharp G, Yarnold JR. Hypoxia can be detected in irradiated normal human tissue: a study using the hypoxic marker pimonidazole hydrochloride. Br J Radiol 2007; 80:934-8. [PMID: 17908818 DOI: 10.1259/bjr/25046649] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Chronic tissue hypoxia may play a role in the pathogenesis of late radiation fibrosis. In order to investigate this hypothesis, the immunohistochemical distribution of pimonidazole hydrochloride (n = 14 patients) and carbonic anhydrase IX (CAIX) (n = 38 patients) was studied in samples of previously irradiated normal human tissue. One sample of irradiated breast tissue, which also showed marked histological features of radiation injury, stained positive for pimonidazole hydrochloride. No CAIX staining was seen in irradiated tissue other than some evidence of physiological hypoxia in the epidermis of two samples of irradiated skin; both were positive for pimonidazole and one was focally positive for CAIX. Pimonidazole hydrochloride staining of tissue with morphological changes of radiation injury could support a role for hypoxia in the pathogenesis of late normal tissue fibrosis in humans.
Collapse
Affiliation(s)
- C B Westbury
- Department of Radiotherapy, The Royal Marsden Hospital, Sutton, Surrey, UK
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Jones RL, Salter J, Nerurkar A, Parton M, A’Hern R, Smith IE, Dowsett M. Prognostic (Px) significance of Ki67 before and after neoadjuvant chemotherapy (CT) in early breast cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.573] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
573 Background: High levels of the proliferation marker Ki67 are associated with a higher response rate to CT but poorer long-term outcome. The Px significance of Ki67 before CT and at surgical excision was compared. Methods: 103 patients treated with CT with pre- and post- (excision) CT tissue and a further 181 with only excision tissue available were identified, 37 and 76 of these respectively were ER+ and also received tamoxifen. The following factors were considered pre-CT and at excision (where relevant) for their relationship with relapse-free (RFS) and overall (OS) survival: ER, PR, HER2, grade, Ki67, histological type, vascular invasion, age/menses, T and N stage, pre-therapy operability, clinical response, CT regimen, type of surgery, adjuvant therapy, pathological tumour size and nodal involvement. Results: In the paired cohort univariate analysis of RFS the following factors were associated with poorer Px (a) pre-CT: ER- (p=0.003); increasing T stage (p<0.001), N stage (p=0.002) and Ki67 (p<0.001); (b) at excision: increasing grade (p=0.01), tumour size (p=0.02), nodal status (p<0.001) and Ki67 (p<0.001); no adjuvant endocrine therapy (p<0.001). On multivariate analysis only excision Ki67 (p<0.001) was significant although there was a suggestion pre-therapy Ki67 was important (p<0.10). On univariate analysis of OS the following factors associated with poorer Px (a) pre-CT: ER- (p=0.006); increasing T stage (p<0.001) and Ki67 (p<0.001); (b) at excision: increasing grade (p=0.04), tumour size (p=0.005), nodal status (p<0.03) and Ki67 (p<0.001); no adjuvant endocrine therapy (p=0.001). On multivariate analysis both pre-CT and excision Ki67 were significant independent predictors but the latter was more highly significant. (p<0.02 + p<0.0001, respectively) Assessing the combined group of 284 patients, after 5 years the highest and lowest tertiles of excision Ki67 had strikingly different Px: RFS 36% and 73%; OS 50% and 85%, respectively. Conclusions: Ki67 after CT is a strong predictor of long-term outcome. The greater significance of Ki67 in the excision sample may be due to this identifying patients in whom residual highly proliferative disease remains after CT. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. L. Jones
- Royal Marsden Hospital, London, United Kingdom
| | - J. Salter
- Royal Marsden Hospital, London, United Kingdom
| | - A. Nerurkar
- Royal Marsden Hospital, London, United Kingdom
| | - M. Parton
- Royal Marsden Hospital, London, United Kingdom
| | - R. A’Hern
- Royal Marsden Hospital, London, United Kingdom
| | - I. E. Smith
- Royal Marsden Hospital, London, United Kingdom
| | - M. Dowsett
- Royal Marsden Hospital, London, United Kingdom
| |
Collapse
|
22
|
Griebsch I, Brown J, Boggis C, Dixon A, Dixon M, Easton D, Eeles R, Evans DG, Gilbert FJ, Hawnaur J, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Potterton J, Thompson D, Turnbull LW, Walker LG, Warren R, Leach MO. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br J Cancer 2006; 95:801-10. [PMID: 17016484 PMCID: PMC2360541 DOI: 10.1038/sj.bjc.6603356] [Citation(s) in RCA: 93] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
Contrast enhanced magnetic resonance imaging (CE MRI) is the most sensitive tool for screening women who are at high familial risk of breast cancer. Our aim in this study was to assess the cost-effectiveness of X-ray mammography (XRM), CE MRI or both strategies combined. In total, 649 women were enrolled in the MARIBS study and screened with both CE MRI and mammography resulting in 1881 screens and 1–7 individual annual screening events. Women aged 35–49 years at high risk of breast cancer, either because they have a strong family history of breast cancer or are tested carriers of a BRCA1, BRCA2 or TP53 mutation or are at a 50% risk of having inherited such a mutation, were recruited from 22 centres and offered annual MRI and XRM for between 2 and 7 years. Information on the number and type of further investigations was collected and specifically calculated unit costs were used to calculate the incremental cost per cancer detected. The numbers of cancer detected was 13 for mammography, 27 for CE MRI and 33 for mammography and CE MRI combined. In the subgroup of BRCA1 (BRCA2) mutation carriers or of women having a first degree relative with a mutation in BRCA1 (BRCA2) corresponding numbers were 3 (6), 12 (7) and 12 (11), respectively. For all women, the incremental cost per cancer detected with CE MRI and mammography combined was £28 284 compared to mammography. When only BRCA1 or the BRCA2 groups were considered, this cost would be reduced to £11 731 (CE MRI vs mammography) and £15 302 (CE MRI and mammography vs mammography). Results were most sensitive to the unit cost estimate for a CE MRI screening test. Contrast-enhanced MRI might be a cost-effective screening modality for women at high risk, particularly for the BRCA1 and BRCA2 subgroups. Further work is needed to assess the impact of screening on mortality and health-related quality of life.
Collapse
Affiliation(s)
- I Griebsch
- MRC Health Services Research Collaboration, Department of Social Medicine, University of Bristol, Bristol, UK
| | - J Brown
- MRC Health Services Research Collaboration, Department of Social Medicine, University of Bristol, Bristol, UK
| | - C Boggis
- Nightingale Centre, Withington Hospital, Manchester, UK
| | - A Dixon
- Addenbrooke's Hospital, Cambridge, UK
| | - M Dixon
- Western General Hospital, Edinburgh, UK
| | - D Easton
- CRC Genetic Epidemiology Unit, Cambridge, UK
| | - R Eeles
- MARIBS Study Office, Section Magnetic Resonance, The Institute of Cancer Research & the Royal Marsden NHS Trust, Downs Road, Sutton, Sussey SM2 5PT, UK
| | - D G Evans
- Regional Genetics Service, Manchester, UK
| | - F J Gilbert
- Department of Radiology, University of Aberdeen, Aberdeen, UK
| | - J Hawnaur
- Department of Clinical Radiology, Manchester Royal Infirmary, Manchester, UK
| | - P Kessar
- MARIBS Study Office, Section Magnetic Resonance, The Institute of Cancer Research & the Royal Marsden NHS Trust, Downs Road, Sutton, Sussey SM2 5PT, UK
| | - S R Lakhani
- Discipline of Molecular & Cellular Pathology, School of Medicine, University of Queensland Mayne Medical School, Australia
| | - S M Moss
- MARIBS Study Office, Section Magnetic Resonance, The Institute of Cancer Research & the Royal Marsden NHS Trust, Downs Road, Sutton, Sussey SM2 5PT, UK
| | | | - A R Padhani
- The Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, UK
| | - L J Pointon
- MARIBS Study Office, Section Magnetic Resonance, The Institute of Cancer Research & the Royal Marsden NHS Trust, Downs Road, Sutton, Sussey SM2 5PT, UK
| | - J Potterton
- MRI Unit, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK
| | - D Thompson
- CRC Genetic Epidemiology Unit, Cambridge, UK
| | - L W Turnbull
- Centre for Magnetic Resonance Investigations, Hull Royal Infirmary, Hull, UK
| | - L G Walker
- Institute of Rehabilitation, University of Hull, Hull, UK
| | - R Warren
- Addenbrooke's Hospital, Cambridge, UK
| | - M O Leach
- MARIBS Study Office, Section Magnetic Resonance, The Institute of Cancer Research & the Royal Marsden NHS Trust, Downs Road, Sutton, Sussey SM2 5PT, UK
- E-mail:
| |
Collapse
|
23
|
Gui GPH, Joubert DJ, Reichert R, Ward A, Lakhani S, Osin P, Nerurkar A, A'Hern R, Benson K, Underwood SR. Continued axillary sampling is unnecessary and provides no further information to sentinel node biopsy in staging breast cancer. Eur J Surg Oncol 2005; 31:707-14. [PMID: 15993028 DOI: 10.1016/j.ejso.2005.04.014] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2005] [Accepted: 04/22/2005] [Indexed: 11/29/2022] Open
Abstract
INTRODUCTION Sentinel lymph node biopsy (SLNB) has become increasingly accepted as a diagnostic method to stage the axilla in breast cancer, selecting women with a positive sentinel node for completion axillary clearance. As SLNB became established, many surgeons supplemented SLNB to sample a minimum of four lymph nodes, on the assumption that the four-node technique is supported by randomised trial data. We hypothesised that the practice of undirected sampling to supplement SLNB adds little information to the status of the residual axilla. METHODS One hundred and sixty-five patients with early breast cancer were studied. Following successful identification of the sentinel node, 84 women had completion axillary dissection and 81 women had an axillary sample with at least four nodes available for pathological assessment. RESULTS Following successful identification of the sentinel node in 165 patients, the false negative rate (FNR) was 2/44=4.5% (95% CI 0.6-15.5), sensitivity 42/44=95.5% (84.5-99.4) and negative predictive value (NPV) 121/123=98.4% (94.2-99.8). In the axillary dissection cohort, the FNR was 2/26=7.7% (0.9-25.1), sensitivity 24/26=92.3% (74.9-99.1) and NPV 58/60=96.7% (88.5-100). In the axillary sample group, the FNR was 0/18=0% (0-18.5), sensitivity 18/18=100% (81.5-100) and NPV 63/63=100% (94.3-100). The SLNB was the only positive node in 12/26 (46.2%) in the axillary dissection group and 10/18 (55.6%) in the axillary sampling group. There was no patient in the axillary sampling group where the sample node was positive and the sentinel node negative. CONCLUSION Once SLNB is validated within the multidisciplinary unit, undirected sampling of the axilla following identification of the sentinel node(s) is unnecessary. The additional sampling of non-sentinel nodes has no role to play either in the assessment of a potential false negative SLNB nor as predictive information on the status of the residual axillary nodes.
Collapse
Affiliation(s)
- G P H Gui
- Academic Surgery and Breast Unit, Royal Marsden NHS Foundation Trust, 203, Fulham Road, London SW3 6JJ, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Leach MO, Boggis CRM, Dixon AK, Easton DF, Eeles RA, Evans DGR, Gilbert FJ, Griebsch I, Hoff RJC, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Thompson D, Warren RML. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365:1769-78. [PMID: 15910949 DOI: 10.1016/s0140-6736(05)66481-1] [Citation(s) in RCA: 671] [Impact Index Per Article: 35.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Women genetically predisposed to breast cancer often develop the disease at a young age when dense breast tissue reduces the sensitivity of X-ray mammography. Our aim was, therefore, to compare contrast enhanced magnetic resonance imaging (CE MRI) with mammography for screening. METHODS We did a prospective multicentre cohort study in 649 women aged 35-49 years with a strong family history of breast cancer or a high probability of a BRCA1, BRCA2, or TP53 mutation. We recruited participants from 22 centres in the UK, and offered the women annual screening with CE MRI and mammography for 2-7 years. FINDINGS We diagnosed 35 cancers in the 649 women screened with both mammography and CE MRI (1881 screens): 19 by CE MRI only, six by mammography only, and eight by both, with two interval cases. Sensitivity was significantly higher for CE MRI (77%, 95% CI 60-90) than for mammography (40%, 24-58; p=0.01), and was 94% (81-99) when both methods were used. Specificity was 93% (92-95) for mammography, 81% (80-83) for CE MRI (p<0.0001), and 77% (75-79) with both methods. The difference between CE MRI and mammography sensitivities was particularly pronounced in BRCA1 carriers (13 cancers; 92%vs 23%, p=0.004). INTERPRETATION Our findings indicate that CE MRI is more sensitive than mammography for cancer detection. Specificity for both procedures was acceptable. Despite a high proportion of grade 3 cancers, tumours were small and few women were node positive. Annual screening, combining CE MRI and mammography, would detect most tumours in this risk group.
Collapse
Affiliation(s)
- M O Leach
- MARIBS Study Office, Section of Magnetic Resonance, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Gui GPH, Behranwala KA, Abdullah N, Seet J, Osin P, Nerurkar A, Lakhani SR. The inframammary fold: contents, clinical significance and implications for immediate breast reconstruction. ACTA ACUST UNITED AC 2004; 57:146-9. [PMID: 15037170 DOI: 10.1016/j.bjps.2003.11.030] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2003] [Accepted: 11/28/2003] [Indexed: 11/23/2022]
Abstract
The amount of breast tissue within the inframammary fold (IMF) is controversial. Preservation of the IMF during mastectomy facilitates breast reconstruction and led some surgeons to practice conservation of the IMF, contrary to traditional descriptions of total mastectomy. The aim of this study was to analyse the clinical significance of IMF tissue content. A total of 50 IMF specimens were studied from 42 patients who underwent mastectomy between January 2001 and December 2002. The amount of breast tissue within each IMF was evaluated. The median patient age was 46 (range 33-86) years. The median body mass index was 23.4 (18.1-38.3)kg/m(2). The median IMF volume resected was 2 (0.2-9.7)cm(3) which was 0.6 (0.1-2.0)% of the breast volume. Ten specimens (20%) contained breast tissue and one (2%) contained breast tissue and an inframammary lymph node. Three specimens (6%) containing fibrofatty tissue without breast parenchyma had intramammary lymph nodes within the IMF. One patient (2%) who had a mastectomy for invasive ductal carcinoma had IMF tissue containing a lymph node within the IMF with breast cancer metastasis. The presence of breast tissue or lymph nodes within the IMF was unrelated to patient age, body mass index, the amount of IMF tissue in relation to breast volume and absolute breast size. Our finding that breast tissue and intramammary lymph nodes are present in 28% of IMF specimens requires re-consideration of the safety of preserving the IMF at mastectomy. If IMF tissue is resected and the immediate breast reconstruction is performed, the superficial fascial system should be reconstructed after excision of the IMF tissue in order to recreate the inframammary crease.
Collapse
Affiliation(s)
- G P H Gui
- Department of Academic Surgery (Breast Unit), Royal Marsden NHS Trust, London, UK.
| | | | | | | | | | | | | |
Collapse
|
26
|
Abstract
Non-Hodgkin s lymphomas (NHLs) constitute a heterogeneous group of lymphoid neoplasms and a majority of them in India are of B-cell phenotype. Varying numbers of T lymphocytes and natural killer (NK) cells are consistently present within the lymph nodes (LNs). The role of these reactive cells is becoming understood. TIA-1 is a cytotoxic granule associated RNA binding protein, the expression of which is restricted to cytotoxic T lymphocytes (CTLs) and NK cells. Snap frozen lymph node biopsies obtained from 41 B-cell NHLs were localized for intra-tumoral TIA-1 + cytolytic cells by immunohistochemistry. Distribution of T cell subsets and NK cells were also quantified. Cells expressing TIA-1 antigen was observed in all the cases, seen as a strong granular cytoplasmic signal. Results indicate significantly higher number of TIA-1 cytolytic cells outside (periphery of the follicle and interfollicular areas) than within the neoplastic follicle in follicular lymphomas (p<0.001). In small lymphocytic lymphomas, cytolytic cells were mainly seen as uniformly scattered single cells, distributed throughout the tumor environment. In mantle cell and diffuse large B-cell lymphomas these were most often seen as small clusters and less frequently as singly scattered cells. Higher numbers of CD4 + than the CD8 + T cells were observed in most cases. Contrary to the follicles in follicular hyperplasia, CD57 + NK cells were predominantly observed outside the neoplastic follicle in follicular lymphomas (FLs). These results outline specific interactions between the potential anti-tumoral cytolytic and the malignant cells of B-cell NHLs.
Collapse
MESH Headings
- Adult
- Aged
- CD4-CD8 Ratio
- CD57 Antigens/analysis
- Female
- Humans
- Immunohistochemistry
- Killer Cells, Natural/chemistry
- Killer Cells, Natural/immunology
- Lymph Nodes/immunology
- Lymph Nodes/pathology
- Lymphocytes, Tumor-Infiltrating/chemistry
- Lymphocytes, Tumor-Infiltrating/immunology
- Lymphoma, B-Cell/immunology
- Lymphoma, B-Cell/pathology
- Lymphoma, Follicular/immunology
- Lymphoma, Follicular/pathology
- Lymphoma, Non-Hodgkin/immunology
- Lymphoma, Non-Hodgkin/pathology
- Male
- Membrane Proteins/analysis
- Middle Aged
- Poly(A)-Binding Proteins
- Proteins
- RNA-Binding Proteins/analysis
- T-Cell Intracellular Antigen-1
- T-Lymphocyte Subsets/chemistry
- T-Lymphocyte Subsets/immunology
- T-Lymphocytes, Cytotoxic/chemistry
- T-Lymphocytes, Cytotoxic/immunology
Collapse
Affiliation(s)
- S Perambakam
- Tata Memorial Centre, Cancer Research Institute, Parel, Mumbai, India
| | | | | | | |
Collapse
|